Dr. Martens PLC — Director's Dealing 2026

Jun 2, 2026

National Storage Mechanism | Additional information

RNS Number : 5226G

Dr. Martens PLC

02 June 2026

Dr. Martens plc (the 'Company')

Director / PDMR Shareholding

Notification of Transactions by Directors / Persons Discharging Managerial Responsibility

The Company announces that, on 29 May 2026, the following directors / persons discharging managerial responsibility ('PDMR') were granted Performance Share Awards (the 'Awards') under the Company's Long Term Incentive Plan (the 'LTIP').

PDMR	Number of Shares
Ije Nwokorie	2,732,653
Giles Wilson	2,100,151

The Awards will vest subject to the achievement of three equally weighted targets, namely cumulative earnings per share, relative total shareholder return and operating cash conversion, over three years. On vesting, the Awards will be subject to a further two-year holding period. No consideration was paid for the grant of the Awards and no price is payable on the exercise of the Awards.

Full details of the target ranges are set out in the Directors' Remuneration Report in the 2026 Annual Report & Accounts, which is available on the Company's website at www.drmartensplc.com.

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Ije Nwokorie

2

Reason for the notification

a)

Position/status

PDMR (Chief Executive Officer)

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Nature of the transaction

Grant of performance share award under the Dr. Martens Long Term Incentive Plan

c)

Price(s) and volume(s)

	Price(s)	Volume(s)
	Nil	2,732,653

d)

Aggregated information

-	Aggregated volume
-	Price

2,732,653

Nil

e)

Date of the transaction

29 May 2026

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Giles Wilson

2

Reason for the notification

a)

Position/status

PDMR (Chief Financial Officer)

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Nature of the transaction

Grant of performance share award under the Dr. Martens Long Term Incentive Plan

c)

Price(s) and volume(s)

	Price(s)	Volume(s)
	Nil	2,100,151

d)

Aggregated information

-	Aggregated volume
-	Price

2,100,151

Nil

e)

Date of the transaction

29 May 2026

f)

Place of the transaction

Outside of a trading venue

For further information, please contact:

Paul Rolling, Head of Secretariat

+447584243562

Bethany Barnes, Director of Investor Relations and Corporate Communications

+447825187465

ENDS

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.

A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections range from its Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz, and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories.

Every Dr. Martens product reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand stays as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.

For more information, visit www.drmartens.com or www.drmartensplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUAOSRNRUNRAR